Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Obstructive benign prostatic hyperplasia: therapeutical aspects

J E Altwein1

  • 1Department of Urology, Hospital Barmherzige Brüder, Munich-Nymphenburg, Germany.

European Urology
|August 15, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unusually large numbers needed to treat for radical prostatectomy in prostate cancer patients with PSA velocity ≤2 ng/ml/year.

Urologia internationalis·2012
Same author

[LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].

Aktuelle Urologie·2009
Same author

[Primary prevention of bladder cancer. What's new?].

Der Urologe. Ausg. A·2007
Same author

[Local recurrence of prostate cancer: hormone therapy].

Der Urologe. Ausg. A·2006
Same author

Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications.

Urologia internationalis·2006
Same author

[Fortuitous finding microhematuria].

MMW Fortschritte der Medizin·2005
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
Same journal

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

European urology·2026
See all related articles

Choosing the right treatment for benign prostatic obstruction (BPO) is key. Surgery offers reliability, while medications like alpha-blockers or finasteride help manage lower urinary tract symptoms (LUTS) effectively.

Area of Science:

  • Urology
  • Medical Therapeutics

Background:

  • Benign prostatic obstruction (BPO) presents urologists with multiple therapeutic choices.
  • Treatment decisions depend on patient preference, efficacy, durability, cost, and physician experience.

Purpose of the Study:

  • To construct a therapeutic spectrum for individualizing BPO treatment options.
  • To evaluate relevant factors based on published studies for optimal patient care.

Main Methods:

  • Development of a therapeutic spectrum for BPO management.
  • Review of published studies to assess various treatment modalities.

Main Results:

  • Transurethral resection of the prostate (TURP) and transurethral incision of the prostate (TUIP) remain reliable surgical options in experienced hands, balancing cost-efficacy and durability.

Related Experiment Videos

  • Alpha-blockers or finasteride are effective for lower urinary tract symptoms (LUTS) without significant obstruction, outperforming watchful waiting for symptom relief and uroflow improvement.
  • Interventional therapies, including high-energy transurethral microwave thermotherapy (TUMT) and ablation techniques like Holmium laser and transurethral vaporisation of the prostate (TEVAP), show limitations in overcoming obstruction or lack long-term durability data.

    • Conclusions:

    • Inappropriate treatment selection for BPO can lead to a cascade of therapies.
    • Future treatment paradigms should emphasize outcomes such as cost, retreatment rates, and quality of life.